Thirty Madison

thirtymadison.com →

-55%

est. 2Y upside i

Healthcare

Healthcare platform for specialized chronic condition treatment

Rank

#2650

Sector

HealthTech

Est. Liquidity

~2Y

Data Quality

Data: Medium

The combined Remedy Meds and Thirty Madison entity operates in a fast-growing digital health market, with Remedy Meds generating over $450M in revenue and Thirty Madison over $220M, both profitable.

Last updated: March 10, 2026

Bull (30%)+100%

Successful integration of Thirty Madison's specialized brands with Remedy Meds' high-growth GLP-1 platform drives significant market share gains and expands the combined entity's reach. The company achieves strong profitability and a successful IPO at a valuation of $1 billion or more, doubling the value of the Thirty Madison asset within the combined entity.

Base (35%)+50%

The combined Remedy Meds and Thirty Madison entity maintains its competitive position in the digital health market, with steady growth across its diverse brand portfolio. Integration proceeds smoothly, leading to a modest increase in valuation to $750 million for the Thirty Madison asset within Remedy Meds, potentially through a later-stage private funding round or a conservative IPO.

Bear (35%)-40%

Intensified competition from incumbents like Hims & Hers and Teladoc, coupled with potential regulatory headwinds for GLP-1 medications or integration challenges between Thirty Madison and Remedy Meds, leads to slower-than-expected growth and operational inefficiencies. The value of the Thirty Madison asset within Remedy Meds declines to $300 million, resulting in a significant loss for equity holders.

Est. time to liquidity~1.5 years
Adjusted for competitive dynamics: 29% (raw: -55%, adjustment: -5%)

Preference Stack Risk

severe

Funding Intensity

42%

Thirty Madison raised $210 million in total funding, which represents 42% of its $500 million acquisition valuation. This indicates that a significant portion of the acquisition value would have been distributed to preferred shareholders before common stockholders.

Dilution Risk

high

As Thirty Madison was acquired in an all-stock deal, its prior shareholders converted to Remedy Meds stock. Future capital raises by the combined Remedy Meds entity, especially before an IPO, could lead to further dilution of existing equity.

Secondary Liquidity

none

Remedy Meds is a private company, and there is currently no established secondary market for employees to sell their shares before a liquidity event such as an IPO or another acquisition.

Other — 2 roles

View all 2 open roles at Thirty Madison →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Thirty Madison's data — designed to show you've done your homework.

  • 1

    “Given the highly competitive landscape with players like Hims & Hers and Teladoc, how does the combined Remedy Meds and Thirty Madison entity plan to differentiate and maintain market share, especially in the rapidly evolving GLP-1 space?”

  • 2

    “With Thirty Madison's historical valuation decline from $1 billion to $500 million at acquisition, what specific strategies are in place to ensure the combined entity achieves and sustains a higher valuation, particularly leading up to a potential IPO?”

  • 3

    “Considering the all-stock acquisition of Thirty Madison by Remedy Meds and the stated goal of an IPO within 12-18 months, how is the company thinking about employee equity, potential dilution, and liquidity events for new hires?”

Community

Valuation Sentiment

Our model estimates -55% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.